Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
We recruited 34 patients with advanced cervical cancer receiving two cycles of platinum-based chemotherapy plus anlotinib and penpulimab, followed by maintenance therapy solely with anlotinib and penpulimab, and showed safety and efficacy of this deescalation regimen. This work highlights the potential for personalized treatment strategies and feasibility of reduced-toxicity regimens.
Authors
- Shengtao Zhou (ORCID: https://orcid.org/0000-0001-8322-5536)
- Xiaoxia Huang (ORCID: https://orcid.org/0009-0005-5607-1419)
- Z.X. Wang (ORCID: https://orcid.org/0009-0004-5291-0441)
- Yingtao Lin (ORCID: https://orcid.org/0000-0001-9168-0491)
- Yuqin Wang (ORCID: https://orcid.org/0009-0003-4323-0447)
- Yajuan Fu (ORCID: https://orcid.org/0000-0002-9461-7030)
- Qin Xu (ORCID: https://orcid.org/0000-0002-3689-0266)
- Lele Zang (ORCID: https://orcid.org/0000-0002-4151-3182)
- Peiwei Li (ORCID: https://orcid.org/0000-0001-7875-9576)
- Dan Hu (ORCID: https://orcid.org/0000-0002-6288-816X)
- Peidong Zhang (ORCID: https://orcid.org/0000-0001-5353-9622)
- Yanhong Zhuo (ORCID: https://orcid.org/0009-0001-9331-6025)
- Meijia Zhu (ORCID: https://orcid.org/0009-0000-5829-9437)
- Huaiwu Lu (ORCID: https://orcid.org/0000-0002-7668-3333)
- Lele Chang (ORCID: https://orcid.org/0000-0002-1305-9058)
- Meifang Ke (ORCID: https://orcid.org/0009-0003-1674-6878)
- Huiqi Zhang (ORCID: https://orcid.org/0009-0003-9444-4090)
- Jing Liu (ORCID: https://orcid.org/0009-0001-5132-7236)
- Ying Chen (ORCID: https://orcid.org/0009-0002-0006-3274)
- Yanhong Wang (ORCID: https://orcid.org/0000-0001-8152-0574)
- Qin Liu (ORCID: https://orcid.org/0000-0002-5416-1198)
- Zhengrong Deng (ORCID: https://orcid.org/0009-0006-4555-7517)
- Songhua Huang (ORCID: https://orcid.org/0009-0005-1205-4465)
- Yang Sun (ORCID: https://orcid.org/0000-0002-1587-9797)
- Yunyun Liu (ORCID: https://orcid.org/0000-0001-8437-6803)
- Cong Wang (ORCID: https://orcid.org/0000-0002-6700-1775)
- Li Li (ORCID: https://orcid.org/0009-0003-4108-4642)
- Li Chen (ORCID: https://orcid.org/0009-0000-3815-0723)
- Xingyun Xie (ORCID: https://orcid.org/0009-0001-2561-555X)
- Fei Zhu (ORCID: https://orcid.org/0009-0008-7386-9125)
- Yaxin Kang (ORCID: https://orcid.org/0009-0009-7585-5250)
Institutions
- Fujian Normal University (CN)
- Fujian Medical University (CN)
- Sun Yat-sen University (CN)
- Sichuan University (CN)
- West China Second University Hospital of Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Sun Yat-sen Memorial Hospital (CN)
- Zhangzhou Municipal Hospital of Fujian Province (CN)
- Shandong Provincial Hospital (CN)
- Fuzhou Second Hospital (CN)
- Second Affiliated Hospital of Fujian Medical University (CN)
- Fujian Provincial Cancer Hospital (CN)
- Sanming University (CN)
- Shandong First Medical University (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Cancer Discovery
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1158/2159-8290.cd-25-1315
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00